ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PCR | 17.85 | N/A | N/A |
| Simplify VettaFi Private Credit Strategy ETF (PCR) | |||
| MMIT | 23.84 | -0.06 | -0.25% |
| NYLIM MacKay Muni Intermediate ETF (MMIT) | |||
| TDSC | 28.06 | -0.14 | -0.49% |
| ETC Cabana Target Drawdown 10 ETF (TDSC) | |||
| BCPL | 23.98 | -0.17 | -0.68% |
| BNY Mellon Core Plus ETF (BCPL) | |||
| WAR | 25.46 | -0.29 | -1.12% |
| U.S. Global Technology and Aerospace and Defense ETF | |||
A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.
| Ticker / NAME | Correlation To ICCC | 1D Price Change % | ||
|---|---|---|---|---|
| ICCC | 100% | +0.39% | ||
| NKTX - ICCC | 43% Loosely correlated | -15.09% | ||
| JANX - ICCC | 27% Poorly correlated | -5.64% | ||
| BOLT - ICCC | 26% Poorly correlated | -2.02% | ||
| NERV - ICCC | 24% Poorly correlated | -5.32% | ||
| IMMP - ICCC | 23% Poorly correlated | -8.95% | ||
More | ||||
a developer of products for cattle health
Industry Biotechnology
ICCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 38 cases where ICCC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 58 cases where ICCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on ICCC as a result. In 90 of 122 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
ICCC moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in 185 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 113 of 140 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The 10-day RSI Indicator for ICCC moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ICCC turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.837) is normal, around the industry mean (3.498). ICCC has a moderately high P/E Ratio (122.500) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (8.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.847) is also within normal values, averaging (440.869).